NCT01837420View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Psoriasis
Interventions
DRUG

VB-201 80mg

DRUG

VB-201 160mg

DRUG

Placebo

Trial Locations (4)

Unknown

VBL Investigative Site, Kiel

VBL Investigative Site, Netanya

VBL Investigative Site, Warsaw

VBL Investigative Site, Barcelona

All Listed Sponsors
lead

Vascular Biogenics Ltd. operating as VBL Therapeutics

INDUSTRY

NCT01837420 - A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis | Biotech Hunter | Biotech Hunter